US drugmaker Pfizer is to offer its full portfolio of drugs, including off-patent medicines like chemotherapies and oral cancer treatments, on a not-for-profit basis to 45 low-income countries around the world.
The company will offer a total of 500 products as an expansion of its “An accord for a healthier world” programme, aimed at increasing access to innovative treatments in some of the poorest countries.
Initially launched in May 2022, at the time, the programme offered only its patented medicines including Covid-19 treatment Paxlovid and its big-selling breast cancer drug, Ibrance, at a not-for-profit price, reports Reuters.
See more from MedicalBrief archives:
Pfizer pledges cost price drugs to 45 lower-income countries
Pfizer to deliver generic version of its COVID pill to 95 countries
Big Pharma's bad image gets a vaccine make-over